HTG MOLECULAR DIAGNOSTICS, INC: Nasdaq/NYSE listing notice — Nasdaq notifies HTG Molecular of delisting risk for equity below $2.5M

HTG MOLECULAR DIAGNOSTICS, INC

Nasdaq notice on May 18, 2023: stockholders' equity fell below $2.5M as of March 31, 2023.
Company must submit a compliance plan by July 3, 2023 under Nasdaq Rule 5550(b).
If plan is accepted, Nasdaq may grant up to 180-day extension for evidence of compliance.
No assurance of regaining compliance; delisting remains a possibility.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.98

HTG MOLECULAR DIAGNOSTICS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: stockholders equity
Rules: 5550(b)

Exact text from the filing

May 18, 2023, HTG Molecular Diagnostics, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) that, as a result of the Company’s stockholders’ equity falling below $2.5 million, as reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirement set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”). Pursuant to the Notice and Nasdaq rules, the Company has 45 calendar days, or until July 3, 2023, to submit a plan to regain compl

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0000950170-23-023963

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.